Charles Kendall Stover

Charles Kendall Stover

Auto-generated profile, based on publicly available information

Charles Kendall Stover

Department of Infectious Diseases, MedImmune, LLC, Gaithersburg, MD, 20878, USA

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2000 in Nature
Verified
Journal Article
Open access
PDF file
CSC. K. Stover
C. K. Stover
XPX. Q. Pham
X. Q. Pham
AEA. L. Erwin
A. L. Erwin
SMS. D. Mizoguchi
S. D. Mizoguchi
PWP. Warrener
P. Warrener
MOM. V. Olson
M. V. Olson
Pseudomonas aeruginosa is a ubiquitous environmental bacterium that is one of the top three causes of opportunistic human infections. A major factor in its prominence as a pathogen is its intrinsic resistance to antibiotics and disinfectants. Here we report the complete sequence of P. aeruginosa strain PAO1. At 6.3 million base pairs, this is the largest bacterial genome sequenced, and the sequence provides insights into the basis of the versatility and intrinsic drug resistance of P. aeruginosa. Consistent with its larger genome size and environmental adaptability, P. aeruginosa contains the highest proportion of regulatory genes observed for a bacterial genome and a large number of genes involved in the catabolism, transport and efflux of organic compounds as well as four potential chemotaxis systems. We propose that the size and complexity of the P. aeruginosa genome reflect an evolutionary adaptation permitting it to thrive in diverse environments and resist the effects of a variety of antimicrobial substances.

6 June 1991 in Nature
Verified
Journal Article
Closed access
CSC. K. Stover
C. K. Stover
VCV. F. de la Cruz
V. F. de la Cruz
TFT. R. Fuerst
T. R. Fuerst
JBJ. E. Burlein
J. E. Burlein
LBL. A. Benson
L. A. Benson
BBB. R. Bloom
B. R. Bloom

1 March 1996 in Journal of Bacteriology
Verified
Journal Article
Closed access
PDF file
GMG G Mahairas
G G Mahairas
PSP J Sabo
P J Sabo
MHM J Hickey
M J Hickey
DSD C Singh
D C Singh
CSC K Stover
C K Stover
The live attenuated bacillus Calmette-Guérin (BCG) vaccine for the prevention of disease associated with Mycobacterium tuberculosis was derived from the closely related virulent tubercle bacillus, Mycobacterium bovis. Although the BCG vaccine has been one of the most widely used vaccines in the world for over 40 years, the genetic basis of BCG's attenuation has never been elucidated. We employed subtractive genomic hybridization to identify genetic differences between virulent M. bovis and M. tuberculosis and avirulent BCG. Three distinct genomic regions of difference (designated RD1 to RD3) were found to be deleted from BCG, and the precise junctions and DNA sequence of each deletion were determined. RD3, a 9.3-kb genomic segment present in virulent laboratory strains of M. bovis and M. tuberculosis, was absent from BCG and 84% of virulent clinical isolates. RD2, a 10.7-kb DNA segment containing a novel repetitive element and the previously identified mpt-64 gene, was conserved in all virulent laboratory and clinical tubercle bacilli tested and was deleted only from substrains derived from the original BCG Pasteur strain after 1925. Thus, the RD2 deletion occurred after the original derivation of BCG. RD1, a 9.5-kb DNA segment found to be deleted from all BCG substrains, was conserved in all virulent laboratory and clinical isolates of M. bovis and M. tuberculosis tested. The reintroduction of RD1 into BCG repressed the expression of at least 10 proteins and resulted in a protein expression profile almost identical to that of virulent M. bovis and M. tuberculosis, as determined by two-dimensional gel electrophoresis. These data indicate a role for RD1 in the regulation of multiple genetic loci, suggesting that the loss of virulence by BCG is due to a regulatory mutation. These findings may be applicable to the rational design of a new attenuated tuberculosis vaccine and the development of new diagnostic tests to distinguish BCG vaccination from tuberculosis infection.

1 June 2000 in Nature
Verified
Journal Article
Closed access
PDF file
CSC. Kendall Stover
C. Kendall Stover
PWPaul Warrener
Paul Warrener
DDDonald R. Van Devanter
Donald R. Van Devanter
DSDavid R. Sherman
David R. Sherman
TATaraq M. Arain
Taraq M. Arain
WBWilliam R. Baker
William R. Baker

14 June 1996 in Science
Verified
Journal Article
Closed access
PDF file
DSDavid R. Sherman
David R. Sherman
KMKhisimuzi Mdluli
Khisimuzi Mdluli
MHMark J. Hickey
Mark J. Hickey
TATaraq M. Arain
Taraq M. Arain
SMSheldon L. Morris
Sheldon L. Morris
CSC. Kendall Stover
C. Kendall Stover
Mutations that eliminate KatG catalase-peroxidase activity prevent activation of isoniazid and are a major mechanism of resistance to this principal drug for the treatment of Mycobacterium tuberculosis infections. However, the loss of KatG activity in clinical isolates seemed paradoxical because KatG is considered an important factor for the survival of the organism. Expression of either KatG or the recently identified alkyl hydroperoxidase AhpC was sufficient to protect bacilli against the toxic effects of organic peroxides. To survive during infection, isoniazid-resistant KatG mutants have apparently compensated for the loss of KatG catalase-peroxidase activity by a second mutation, resulting in hyperexpression of AhpC.

12 November 2014 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ADAntonio DiGiandomenico
Antonio DiGiandomenico
AKAshley E. Keller
Ashley E. Keller
CGCuihua Gao
Cuihua Gao
GRGodfrey J. Rainey
Godfrey J. Rainey
PWPaul Warrener
Paul Warrener
CSC. Kendall Stover
C. Kendall Stover
A new antibody platform combining anti-Psl and anti-PcrV activities provides enhanced protection and acts synergistically with antibiotics against Pseudomonas aeruginosa .